AR075881A1 - Composicion farmaceutica.metodo de preparacion - Google Patents
Composicion farmaceutica.metodo de preparacionInfo
- Publication number
- AR075881A1 AR075881A1 ARP100100866A ARP100100866A AR075881A1 AR 075881 A1 AR075881 A1 AR 075881A1 AR P100100866 A ARP100100866 A AR P100100866A AR P100100866 A ARP100100866 A AR P100100866A AR 075881 A1 AR075881 A1 AR 075881A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- composition according
- filler
- different
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicacion 1: Una composicion farmacéutica, la cual comprende: a) una cantidad terapéuticamente efectiva de Alisquireno o una sal farmacéuticamente aceptable del mismo, b) un relleno; y c) uno o más, por ejemplo, de uno a tres rellenos diferentes del relleno b), e independientemente seleccionados a partir de: c1) alditoles; c2) mono-, di-, tri-, y polisacáridos; y c3) un relleno que tenga una densidad a granel asentada en el intervalo de 0.5 a 1.5 g/cm3, y en el entendido de que, si está comprendida la Indigotina Lake en la composicion, no está en una cantidad de 0.13, 0.2, 0.25 o 0.5 miligramos por dosis unitaria. Reivindicacion 6: La composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones anteriores, en la forma de una tableta de dos capas, la cual comprende una capa que contiene a la composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones anteriores, y una segunda capa que comprende un principio farmacéuticamente activo d) que es diferente del componente a). Reivindicacion 7: La composicion farmacéutica de acuerdo con la reivindicacion 6, en donde el principio farmacéuticamente activo d) que es diferente del componente a) es Valsartan o una sal farmacéuticamente aceptable del mismo. Reivindicacion 12: El uso de la composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones anteriores, para el tratamiento de hipertension, insuficiencia cardíaca congestiva, angina, infarto de miocardio, arterioesclerosis, nefropatía diabética, miopatía cardíaca diabética, insuficiencia renal, enfermedad vascular periférica, hipertrofia de ventrículo izquierdo, disfuncion cognitiva, embolia, dolor de cabeza, e insuficiencia cardíaca cronica, en particular hipertension.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16188309P | 2009-03-20 | 2009-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075881A1 true AR075881A1 (es) | 2011-05-04 |
Family
ID=42245650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100866A AR075881A1 (es) | 2009-03-20 | 2010-03-18 | Composicion farmaceutica.metodo de preparacion |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120003308A1 (es) |
| EP (1) | EP2408433A1 (es) |
| JP (1) | JP2012520892A (es) |
| KR (1) | KR20110129482A (es) |
| CN (1) | CN102361633A (es) |
| AR (1) | AR075881A1 (es) |
| AU (1) | AU2010226615A1 (es) |
| BR (1) | BRPI1009131A2 (es) |
| CA (1) | CA2753221A1 (es) |
| MX (1) | MX2011009844A (es) |
| TW (1) | TW201038299A (es) |
| WO (1) | WO2010107966A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120009257A1 (en) * | 2009-03-20 | 2012-01-12 | Indrajit Ghosh | Galenical Formulations of a Fixed Dose Combination of Valsartan and Aliskiren |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| MY144477A (en) * | 2004-03-17 | 2011-09-30 | Novartis Ag | Galenic formulations of organic compounds |
| MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
| AU2008309058B2 (en) * | 2007-09-28 | 2012-08-09 | Novartis Ag | Galenical formulations of Aliskiren and Valsartan |
-
2010
- 2010-03-18 AR ARP100100866A patent/AR075881A1/es unknown
- 2010-03-18 WO PCT/US2010/027748 patent/WO2010107966A1/en active Application Filing
- 2010-03-18 JP JP2012500947A patent/JP2012520892A/ja active Pending
- 2010-03-18 CA CA2753221A patent/CA2753221A1/en not_active Abandoned
- 2010-03-18 AU AU2010226615A patent/AU2010226615A1/en not_active Abandoned
- 2010-03-18 BR BRPI1009131A patent/BRPI1009131A2/pt not_active Application Discontinuation
- 2010-03-18 KR KR1020117024605A patent/KR20110129482A/ko not_active Application Discontinuation
- 2010-03-18 EP EP10711496A patent/EP2408433A1/en not_active Withdrawn
- 2010-03-18 MX MX2011009844A patent/MX2011009844A/es not_active Application Discontinuation
- 2010-03-18 CN CN2010800126194A patent/CN102361633A/zh active Pending
- 2010-03-18 US US13/256,462 patent/US20120003308A1/en not_active Abandoned
- 2010-03-19 TW TW099108210A patent/TW201038299A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012520892A (ja) | 2012-09-10 |
| BRPI1009131A2 (pt) | 2016-03-01 |
| CN102361633A (zh) | 2012-02-22 |
| AU2010226615A1 (en) | 2011-09-15 |
| US20120003308A1 (en) | 2012-01-05 |
| KR20110129482A (ko) | 2011-12-01 |
| MX2011009844A (es) | 2011-09-29 |
| EP2408433A1 (en) | 2012-01-25 |
| CA2753221A1 (en) | 2010-09-23 |
| WO2010107966A1 (en) | 2010-09-23 |
| TW201038299A (en) | 2010-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2651287T3 (es) | Procedimiento para la estimulación de la angiogénesis, la vascularización o la reparación vascular o para la inhibición de la angiogénesis tumoral | |
| AR066168A1 (es) | Formulaciones galenicas de compuestos organicos | |
| ES2634562T3 (es) | Métodos y composiciones para tratar hiperuricemia y trastornos metabólicos asociados con hiperuricemia | |
| JP2021509912A5 (es) | ||
| PE20120542A1 (es) | Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas | |
| CL2011001848A1 (es) | Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras. | |
| CL2013002241A1 (es) | Compuestos derivados de (4,4´-bifeniilbis(1h-imidazol-4,2-diil)-2,1-pirrolidindiil((1s)-1-((2r,6r)-2,4-dimetilltetrahidro-2h-piran-4-il)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo, inhibidores del vhc; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y uso para tratar una infeccion por vhc. | |
| JP2013166781A5 (es) | ||
| MA38399B2 (fr) | Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique | |
| ECSP13012847A (es) | Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación. | |
| AR124688A2 (es) | Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo | |
| JP2016512817A5 (es) | ||
| CL2012000263A1 (es) | Compuestos derivados de amidas espiro ciclica, agonista b-adrenoreceptor y antagonista muscarinico; utiles en el tratamiento en enfermedades inflamatorias, tales como epoc. | |
| CL2014001534A1 (es) | Combinacion de dosis fija que comprende clorhidrato de benazeprilo y pimobendan en forma de un comprimido de dos capas; procedimiento de fabricacion y uso en el tratamiento de la insuficiencia cardiaca congestiva en perros. | |
| AR077018A1 (es) | Un comprimido de dosis fija del antagonista del receptor de la trombina y el clopidogrel. | |
| AR062979A1 (es) | Formulaciones orales liofilizadas de desintegracion rapida de un antagonista del receptor de trombina | |
| RU2015143475A (ru) | Продукт и способ лечения диареи | |
| JP2012527438A5 (es) | ||
| NZ593622A (en) | Galenic formulations of organic compounds | |
| AR084882A1 (es) | Compuesto de 1-azabiciclo[2.2.2]octano y usos para el tratamiento de esquizofrenia | |
| AR117510A1 (es) | COMBINACIONES DE b-LACTAMA Y PROBENECID Y USOS DE LAS MISMAS | |
| AR075881A1 (es) | Composicion farmaceutica.metodo de preparacion | |
| AR075988A1 (es) | Compuesto de piridiloxi - pirrolidina inhibidor de recaptacion de serotonina y norepinefrina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de dolor cronico | |
| JP2012520302A5 (es) | ||
| PE20091885A1 (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |